X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (6) 6
female (5) 5
humans (5) 5
adult (4) 4
bridged bicyclo compounds, heterocyclic - administration & dosage (4) 4
lymphomas (4) 4
male (4) 4
pharmacology & pharmacy (4) 4
sulfonamides - administration & dosage (4) 4
venetoclax (4) 4
aged (3) 3
aged, 80 and over (3) 3
analysis (3) 3
antineoplastic agents - administration & dosage (3) 3
hematology (3) 3
leukemia, lymphocytic, chronic, b-cell - drug therapy (3) 3
middle aged (3) 3
pharmacology/toxicology (3) 3
rituximab (3) 3
administration, oral (2) 2
antineoplastic agents - adverse effects (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
bcl-2 (2) 2
bridged bicyclo compounds, heterocyclic - adverse effects (2) 2
cancer (2) 2
care and treatment (2) 2
chronic lymphocytic leukemia (2) 2
clinical trials (2) 2
cll (2) 2
cyp3a interactions (2) 2
drug administration schedule (2) 2
fludarabine (2) 2
food effect (2) 2
leukemia (2) 2
lymphoma (2) 2
medicine & public health (2) 2
oncology (2) 2
patients (2) 2
pharmacy (2) 2
population pharmacokinetics (2) 2
recurrence (2) 2
renal and hepatic impairment (2) 2
studies (2) 2
sulfonamides - adverse effects (2) 2
survival (2) 2
treatment outcome (2) 2
update (2) 2
0605 microbiology (1) 1
1108 medical microbiology (1) 1
1115 pharmacology and pharmaceutical sciences (1) 1
3rd trimester (1) 1
aberration (1) 1
abt-199 (1) 1
age (1) 1
allogeneic (1) 1
anti-hiv agents - blood (1) 1
anti-hiv agents - pharmacokinetics (1) 1
anti-hiv agents - pharmacology (1) 1
antimitotic agents (1) 1
antineoplastic agents (1) 1
antineoplastic agents - blood (1) 1
antineoplastic agents - therapeutic use (1) 1
antineoplastic combined chemotherapy protocols - administration & dosage (1) 1
antineoplastic combined chemotherapy protocols - therapeutic use (1) 1
antiretroviral-naive (1) 1
antiviral agents (1) 1
apoptosis (1) 1
area under curve (1) 1
bcl-2 family (1) 1
biochemistry, general (1) 1
biomedicine (1) 1
biotechnology (1) 1
bone marrow (1) 1
bridged bicyclo compounds, heterocyclic - blood (1) 1
bridged bicyclo compounds, heterocyclic - pharmacokinetics (1) 1
bridged bicyclo compounds, heterocyclic - therapeutic use (1) 1
busulfan (1) 1
cancer research (1) 1
cancer therapies (1) 1
cd20 antigen (1) 1
chlorambucil (1) 1
chromatography, high pressure liquid (1) 1
chromosome deletion (1) 1
chronic lymphatic leukemia (1) 1
chronic lymphocytic-leukemia (1) 1
clearance (1) 1
clinical trials, phase i as topic (1) 1
clinical trials, phase ii as topic (1) 1
clinical-phase (1) 1
clinical-trials (1) 1
clofarabine (1) 1
cohort studies (1) 1
confidence intervals (1) 1
cytotoxicity (1) 1
decision making (1) 1
demographics (1) 1
demography (1) 1
development and progression (1) 1
diagnosis (1) 1
dietary fats - administration & dosage (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The AAPS Journal, ISSN 1550-7416, 9/2016, Volume 18, Issue 5, pp. 1192 - 1202
Venetoclax (ABT-199/GDC-0199) is a selective, potent, first-in-class BCL-2 inhibitor that restores apoptosis in cancer cells and has demonstrated clinical... 
Biochemistry, general | Biotechnology | Biomedicine | food effect | Pharmacy | Pharmacology/Toxicology | venetoclax | CYP3A interactions | rituximab | population pharmacokinetics | renal and hepatic impairment
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 10/2016, Volume 78, Issue 4, pp. 847 - 853
Journal Article
CPT: Pharmacometrics & Systems Pharmacology, ISSN 2163-8306, 03/2019, Volume 8, Issue 3, pp. 138 - 145
The use of model‐based drug development (MBDD) has been demonstrated to improve the efficiency of clinical trial design. However, MBDD complexity can limit its... 
Studies | Clinical trials | Probability | Hypotheses | Decision making | Drug dosages | Tutorial
Journal Article
Hematological Oncology, ISSN 0278-0232, 12/2017, Volume 35, Issue 4, pp. 679 - 684
Venetoclax is indicated at a dosage of 400 mg daily (QD) for the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion who have... 
exposure response | chronic lymphocytic leukemia | synergy | venetoclax | rituximab | progression‐free survival | progression-free survival | Recurrence | Rituximab - pharmacokinetics | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Drug Resistance, Neoplasm | Male | Treatment Outcome | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Leukemia, Lymphocytic, Chronic, B-Cell - pathology | Sulfonamides - pharmacokinetics | Drug Synergism | Rituximab - administration & dosage | Retreatment | Rituximab - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Female | Leukemia, Lymphocytic, Chronic, B-Cell - mortality | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Clinical Trials, Phase I as Topic | Sulfonamides - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - pharmacokinetics | Clinical Trials, Phase II as Topic | GERIATRIC ASSESSMENT | OPEN-LABEL | CANCER | FLUDARABINE | PROGNOSTIC INDEX | OLDER PATIENTS | ONCOLOGY | CLINICAL-TRIALS | PHASE-3 TRIAL | HEMATOLOGY | ELDERLY-PATIENTS | CHLORAMBUCIL | Medical research | Care and treatment | Relapse | Patient outcomes | Development and progression | Antineoplastic agents | Diseases | Antimitotic agents | Chronic lymphocytic leukemia | Analysis | Monoclonal antibodies | Medicine, Experimental | Lymphomas | Chronic lymphatic leukemia | Demography | Leukemia | Clinical trials | Rituximab | Chromosome deletion | Exposure | Lymphatic leukemia | Lymphoma | Patients | Survival | Confidence intervals | Demographics | CD20 antigen | Synergistic effect | Aberration
Journal Article
Cancer Research, ISSN 0008-5472, 07/2016, Volume 76, Issue 14 Supplement, pp. 2045 - 2045
Venetoclax is a selective, potent, orally bioavailable, small molecule, B-cell lymphoma-2 (Bcl2) inhibitor that restores apoptosis in cancer cells. Clinical... 
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 08/2019, Volume 25, Issue 8, pp. 1603 - 1610
•Evaluation of clofarabine (clo-fara) pharmacokinetics was performed in a pediatric population.•Body weight and age influence clo-fara clearance.•Young... 
Allogeneic | Hematopoietic cell transplantation | Clofarabine | Fludarabine | Pharmacokinetics | Pediatric | CLEARANCE | MODEL | IMMUNOLOGY | BUSULFAN | TRANSPLANTATION | NUCLEOSIDE TRANSPORTERS | HENT1 | HEMATOLOGY | CYTOTOXICITY | Analysis | Transplantation | Hematopoietic stem cells
Journal Article
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.